Blood Pressure Recovery After Dobutamine Antagonism: Partial With Landiolol, None With Esmolol

Clin Pharmacol Drug Dev. 2022 Mar;11(3):309-317. doi: 10.1002/cpdd.1025. Epub 2021 Oct 16.

Abstract

We investigated the hemodynamic effects of 2 short-acting β1 -blockers, landiolol and esmolol, in the continuous presence of dobutamine in a prospective, single-center, randomized, crossover study in 16 healthy White volunteers. Dobutamine was infused at a rate sufficient to increase the heart rate by at least 30 beats per minute, followed by a 60-minute infusion of 50 μg/kg/min esmolol or 10 μg/kg/min landiolol on top of the unchanged dobutamine infusion. Concentrations of β-blockers and their metabolites in blood, heart rate, and blood pressure were followed for 180 minutes. Landiolol reduced the dobutamine-induced heart rate and blood pressure increases better than esmolol. After discontinuation of β-blocker administration, heart rate recovered swiftly to preinfusion values in both study arms. Systolic and diastolic blood pressure recovered partially after landiolol but showed a continued reduction after esmolol. No serious adverse events were observed. The heart rate effect is characteristic for β-blockers, whereas the blood pressure effects are likely due to direct and indirect β-blocker effects as well as influences on various ion channels. This may explain why landiolol that is devoid of effects on renin and sodium, calcium, and potassium channels behaves different from esmolol with respect to blood pressure recovery.

Keywords: cardioselective β-blocker; dobutamine; esmolol; landiolol; pharmacodynamics.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Pressure
  • Cross-Over Studies
  • Dobutamine* / pharmacology
  • Humans
  • Morpholines
  • Propanolamines
  • Prospective Studies
  • Urea / analogs & derivatives

Substances

  • Morpholines
  • Propanolamines
  • Dobutamine
  • landiolol
  • Urea
  • esmolol